Should I Buy DHR? DHR 2026 Analysis

Should You Buy Danaher Corp (DHR) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Sell

Latest Price

216.610

1 Day change

0.40%

52 Week Range

242.800

Analysis Updated At

2026/02/05

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Not a good buy right now: near-term technicals and positioning lean bearish and the pattern-based forward odds point to further downside.
Price is sitting just above key support (S1 ~218.48); with weak momentum, a support break would likely accelerate selling.
Options sentiment is defensive (put-heavy open interest), and Congress trading shows only recent sales.
Upside case exists longer-term (analysts raising targets; Q4 growth returned), but for an impatient entry, the risk/reward is unfavorable today.

Intellectia Proprietary Trading Signals

AI Stock Picker: no signal on given stock today.
SwingMax: No signal on given stock recently.

Technical Analysis

Trend/Momentum: MACD histogram is negative (-2.461) and only “negatively contracting,” which suggests bearish momentum is easing but not reversed.
RSI: RSI(6) ~35.1 (weak/near-oversold zone), which can allow bounces, but is not a confirmed buy signal by itself.
Moving averages: converging MAs indicate indecision/transition rather than a clean uptrend.
Key levels: Price (~219.5) is barely above S1 218.48; below that, next support is S2 ~212.20. Overhead pivot resistance is ~228.66, then R1 ~238.84.
Quant/pattern read: similar candlestick-pattern cohort implies elevated downside risk (-3.2% next day, -5.66% next week, -14.41% next month).

Options Data

Bearish

Open Interest Put-Call Ratio

Neutral

Option Volume Put-Call Ratio

Sentiment: Open-interest put/call of 1.53 is meaningfully put-skewed (defensive/bearish positioning).
Flow: Volume put/call ~1.05 is slightly put-heavy, aligning with cautious near-term sentiment.
Volatility: IV (30d) ~25.95 vs HV ~26.29 (roughly in-line); IV percentile ~21.5 / IV rank ~11.5 indicates options are relatively cheap vs recent history (not a panic bottom signal).
Activity: Today’s volume is far below the 5d/10d averages (1301 vs 4571/5783), suggesting no strong “capitulation” buying/selling signal in options today.

Technical Summary

Sell

Buy

Positive Catalysts

- Wall Street tone is improving: multiple firms raised price targets post-Q4 while reiterating Buy/Outperform.
- Management/Street narrative: increasing confidence in a 2026 recovery across end markets (life sciences/bioprocessing cited as potential upside areas).
- Sector read-through: the provided news (Revvity) shows solid Q4 execution and constructive 2026 guide in adjacent life-science tools, which can support sentiment for the group.

Neutral/Negative Catalysts

- Near-term technical setup is weak: price is pinned near support with bearish MACD and unfavorable pattern-based forward odds.
- Options positioning is defensive: put-heavy open interest suggests investors are still hedging/downside-protecting.
- Congress trading (last 90 days): 4 sells, 0 buys (cautious signaling from influential participants).
- News feed provided is not company-specific to DHR (it’s about Revvity), so there’s no direct DHR catalyst shown here to flip momentum immediately.

Financial Performance

Latest quarter: 2025/Q4.
Growth returned: Revenue $6.838B (+4.59% YoY), Net income $1.197B (+10.22% YoY), EPS $1.68 (+12.75% YoY).
Margin trend: Gross margin 58% (down ~2.52% YoY) is a watch-item; profitability improved via net income/EPS despite GM compression.
Overall: fundamentals are improving YoY, but the stock’s near-term tape/sentiment is not confirming an “urgent buy” entry.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Recent trend: predominantly positive revisions—multiple price target raises from late Dec through late Jan while maintaining Buy/Outperform stances.
Examples: Deutsche Bank to $270 (Buy), BofA to $270 (Buy), Jefferies to $265 (Buy), Baird to $251 (Outperform), Evercore to $254 (Outperform), Guggenheim to $275 (Buy).
Wall Street pros: recovery/normalization into 2026, possible life sciences/bioprocessing re-acceleration, and a potentially better M&A backdrop.
Wall Street cons: recovery is not yet back to historical growth; cadence/timing of bioprocessing and life-science rebound remains the key debate and can keep the stock range-bound while momentum stays soft.

17 Analyst Rating

Wall Street analysts forecast DHR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DHR is 261.57 USD with a low forecast of 235 USD and a high forecast of 310 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

15 Buy

2 Hold

0 Sell

Strong Buy

Current: 215.750

Low

235

Averages

261.57

High

310

Current: 215.750

Low

235

Averages

261.57

High

310

Baird

NULL -> Outperform

maintain

$247 -> $251

AI Analysis

2026-01-29

Reason

Baird

Price Target

$247 -> $251

AI Analysis

2026-01-29

maintain

NULL -> Outperform

Reason

Baird raised the firm's price target on Danaher to $251 from $247 and keeps an Outperform rating on the shares. The firm updated its model following Q4 results.

Deutsche Bank

NULL -> Buy

upgrade

$250 -> $270

2026-01-29

Reason

Deutsche Bank

Price Target

$250 -> $270

2026-01-29

upgrade

NULL -> Buy

Reason

Deutsche Bank raised the firm's price target on Danaher to $270 from $250 and keeps a Buy rating on the shares.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for DHR

Unlock Now

DHR Should I Buy

DHR Should I Buy

Should You Buy Danaher Corp (DHR) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch